Hello. Welcome to Clover Health's Second Quarter 2026 Earnings Call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. Ryan, you may begin. Good afternoon, everyone. Joining me on our call today to discuss the company's second quarter 2026 results are Andrew Toy, Clover Health's Chief Executive Officer, and Clay Thornton, the company's Interim Chief Financial Officer. You can find today's press release and the accompanying supplemental slides, as well as the company's most recent investor deck in the investor events and presentations section of our website at investors.cloverhealth.com. This webcast is being recorded and a replay will be available in the investor relations section of the Clover Health website. I'd also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the risk factors section of our most recent annual report on Form 10-K and other SEC filings. Information about non-GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures, can be found in the earnings materials available on our website. With that, I'll now turn the call over to Andrew. Thank you, Ryan. Thanks everyone for joining our call today. At Clover, we've always believed the greatest opportunity for AI in healthcare is not simply to make the existing system a little more efficient. It's to help physicians make better decisions for individual patients at the point of care. That's what Clover Assistant does, and our results are increasingly demonstrating that when you improve those decisions at scale, better care, membership growth, and increasing profitability can happen together. The first half of 2026 was another important proof point of this. Through the first six months of the year, we delivered market leading MA membership growth of 48%, while increasing GAAP net income by $67 million year-over-year. At the same time, total revenue in the first half increased by more than $550 million year-over-year to $1.5 billion. Consolidated gross profit increased by $104 million, and we've expanded operating leverage by more than 200 basis points as we've scaled. We believe this performance validates how our AI-powered model not only improves care for members, but also strengthens our underlying business over time. I am proud of our results so far this year and believe we are on a strong path. I want to turn now to where the business is headed. Since our last call, two things have strengthened our confidence in 2027 and beyond. One is the recalculation of our star rating. The other, and ultimately the more important one, is the continued maturation of our member cohorts under Clover Assistant. It's important not to confuse the role each one plays. We believe the higher star rating gives us more flexibility. Cohort maturation is what strengthens the underlying earnings engine. Following the court's order and CMS's subsequent recalculation, all of our Medicare Advantage members are now enrolled in plans rated four and a half stars for payment year 2027. We're pleased with that outcome because we believe it better reflects the quality we have been delivering for years. CMS has filed notice of its intent to appeal the District Court's decision. Because this regards pending litigation, I'll be brief. We believe the District Court's ruling was thorough and well-reasoned, and we are prepared to defend it on appeal. In the meantime, we remain focused on bringing affordable, high-quality care to seniors on Medicare in our four and a half star plans. To be clear, four and a half stars matters. It gives us more room to reinvest in members, maintain a highly competitive product, support growth, and expand profitability. It does not create the economics of our model. Our confidence in 2027 is grounded in the continued cohort maturation under Clover Assistant, which we believe will allow us to grow membership and meaningfully expand profitability. The higher star rating simply gives us more flexibility, allowing us to extend our differentiated model to more Medicare beneficiaries while remaining disciplined in how we balance member value, growth, and profitability. Put another way, the rating gives us more freedom in how we allocate value. Clover Assistant is what creates the value in the first place, and that distinction matters. Our strategy has never been to wait for a favorable rate or rating to make the business work. We built a wide network, full risk PPO model because we believe seniors should be able to get an affordable product without being forced to give up broad physician choice. We also believe that if we wanted to make that model work over the long term, we had to solve one of the hardest problems in healthcare first, how to empower physicians to deliver better clinical care for their patients. That's what Clover Assistant was built to do. It helps physicians use a more complete view of the patient to identify disease earlier, manage chronic conditions more consistently, and make better care decisions over time. Our clinically focused approach has contributed to Clover becoming the top-rated HEDIS PPO plan in the country. Importantly, that same technology not only powers our own Medicare Advantage business, but through Counterpart Health, we're extending that same clinically focused model across the healthcare market. We believe the broader industry is only beginning to recognize what's possible when technology is built around the clinical decision. Now, as we look toward next year, it's too early to provide a specific outlook for 2027, but we feel very good about our growth position heading into next year. The four and a half star rating strengthens our ability to put forth a compelling product, particularly across our core New Jersey and Georgia markets. We can improve the health outcomes and economics of our members, we believe we have a powerful growth engine within those core markets that will sustain us well into the future. That's not to say that we won't expand to more geographies, rather that we do not feel compelled to do so just to chase a top-line growth number. The key thing for 2027 is what happens as members mature under our care model. New members do not arrive with every condition neatly managed, every care gap closed, and every part of their care already coordinated. Over time, Clover Assistant helps physicians deliver that individualized care for each patient to identify disease earlier and make better care decisions. As that happens, we expect the clinical and financial performance of the cohort to improve, and this is exactly what we are seeing. We now have multiple vintages of members who have had CA-driven care for many years, and we believe that provides a compounding tailwind to our business. To set your intuition, we've shared before that our cohorts typically improve by about $70 PMPM in gross profit as they move from year one to year two. It's encouraging to see that progression playing out this year in the large cohort of members that joined in 2025. By 2027, that same cohort will be in year three, and our 2026 cohort will be in year two. That means a much larger portion of our membership base will have had at least one year of Clover Assistant-powered care. This is not simply a matter of having more members. It's a matter of having more members whose conditions we understand better, whose physicians have had more time to act, and whose economics have had more time to mature. That gives us increasing confidence in the earnings potential of the business heading into 2027. Clay will discuss the cohort performance in more detail later in the call. While we're not providing formal 2027 guidance today, the setup is increasingly clear. We expect to enter next year with a larger membership base, a greater proportion of tenured members, more flexibility from our four and a half star rating, and additional operating leverage. Those are not four disconnected points. They reinforce one another because they're all driven by the same underlying care model. We built Clover Assistant to help physicians make better decisions that lead to better care. Better clinical care leads to stronger cohort economics. Because we operate at full risk, those stronger cohort economics create a stronger business. To us, better clinical quality, stronger cohort economics, and a more scalable operating model are all parts of the same system working as intended. We believe that's what makes Clover different, and it's the foundation for how we think about the years ahead. With that, I'll turn the call over to Clay. Thank you, Andrew, and thanks everyone for joining us today. Andrew covered the strategic foundation of the business and why we have increasing confidence in 2027. I'll focus my remarks today on the financial performance and operating indicators behind that confidence, starting with the headline for the quarter. We continue to demonstrate a differentiated combination of growth and profitability in Medicare Advantage. During the second quarter, we grew Medicare Advantage membership 48% year-over-year, while generating $41 million of adjusted EBITDA and $28 million of GAAP net income. Our underlying Medicare Advantage business continues to strengthen, today's increased guidance reflects our strong first half performance and the operating indicators we are seeing across the business. In short, the first half gives us greater confidence that this year's growth is converting into the long-term earnings profile we expected. Let's begin with membership and revenue. Average Medicare Advantage membership increased to 157,000 members during the quarter, driving total revenue of $743 million, an increase of 56% year-over-year. Importantly, our growth remains disciplined and concentrated in the markets where we believe we have the strongest ability to engage members clinically and manage long-term unit economics, particularly across our core New Jersey and Georgia markets. Turning next to gross profit. Consolidated gross profit totaled $153 million during the quarter, representing 54% year-over-year growth. Importantly, the gross profit performance was supported by two things we care most about at this point in the year: favorable trend development and cohort progression. First, medical cost trends are performing better than we expected when we entered the year. Inpatient utilization continues to trend favorably overall, including among our year one members, where utilization is tracking below the comparable new member cohort from a year ago. On outpatient, trends peaked in March and have since moderated in Q2. They remain elevated from prior years but are within our expectations, we continue to monitor closely. We are also seeing continued progress in categories that were specific focus areas for us. Dental cost performance continues to improve following the changes we implemented in how we manage out-of-network dental claims. Part D has also performed better than expected through the first half, now that we are in the second year of IRA implementation, we have stronger visibility into the expected seasonality in that category. Second, more important to how we think about the business, our cohorts are developing well. As illustrated in our supplemental presentation, our historical data shows insurance gross profit improving as members move from year one to year two, again from year two to year three. That framework is especially relevant today because a significant portion of our membership is still in the first two years of its Clover life cycle. This matters because the full earnings power of this year's growth is not realized on day one. It builds as members remain with Clover, as Clover Assistant coverage expands, Clover Care Services engagement deepens. Taken together, favorable trend development and cohort progression give us greater confidence that the growth we delivered this year is converting into the earnings profile we expected. I'll come back to this when I discuss our 2027 outlook. Turning next to SG&A. Adjusted SG&A totaled $112 million during the quarter, representing 15% of total revenue. That's an improvement of approximately 220 basis points compared to the second quarter of 2025. We believe these results continue to demonstrate the operating leverage inherent in our model as we scale. At the same time, we are continuing to make deliberate investments that strengthen both our Medicare Advantage business and Counterpart Health. These investments include continued enhancement of our flagship Clover Assistant product, Counterpart Health's go-to-market capabilities, and targeted investments in health plan operations that we believe will support operating leverage in future years. That is the balance we are focused on, maintaining expense discipline in the core business while funding capabilities that can support growth, clinical performance, and operating leverage over time. Turning next to profitability. Second quarter adjusted EBITDA totaled $41 million, while GAAP net income totaled $28 million. Through the first half of the year, we've now generated $81 million of adjusted EBITDA and $55 million of GAAP net income. Turning briefly to our balance sheet. We ended the quarter with $443 million of cash and investments while continuing to operate with no debt outstanding. Cash flow from operations totaled $133 million through the first half of the year, reinforcing our confidence in our ability to self-fund future growth while further strengthening our balance sheet. Next, I'd like to cover our updated guidance. Following strong first-half performance, we are increasing our full year guidance across all metrics. We now expect average Medicare Advantage membership of 156,000 to 158,000 members, total revenue of $2.92 billion to $3 billion, consolidated gross profit of $525 million to $555 million, adjusted EBITDA of $70 million to $85 million, and GAAP net income of $20 million to $35 million. These updates reflect our increasing confidence in the underlying performance of the business after six months of execution. That said, this remains a balanced outlook, one that recognizes the strength we are seeing while maintaining appropriate discipline in the second half. With a large portion of our membership still in the early stages of our care, we believe it's prudent to allow additional claims experience to emerge before assuming current trends will persist through year-end. We think about the second half of 2026, the expected quarterly shape is consistent with how we plan the business. Within this outlook, we continue to expect consolidated gross profit to be stronger in the third quarter than the fourth quarter, reflecting typical MA seasonality patterns. We also expect investments to increase during the fourth quarter, including AEP-related activities. Taken together, we expect adjusted EBITDA to remain positive in the third quarter before returning to a more typical seasonal loss in the fourth quarter. Importantly, even with that seasonal pattern, our second half outlook represents significant improvement versus last year. The confidence behind this guidance is supported by the same operating framework we laid out earlier this year, which continues to strengthen across five key indicators. First, retention remains high and continues to support favorable underlying economics. Second, we are bringing more members under Clover Assistant-powered primary care while continuing to expand Clover Care Services engagement for our most vulnerable members. Third, underlying utilization trends are stable and continue performing better than our original expectations. Fourth, we are continuing to realize meaningful operating leverage as membership has nearly doubled since 2024. Finally, after the first six months of this year, our 2025 and 2026 cohorts continue developing in line with or ahead of our expectations. Looking ahead now to 2027. We believe the most important financial driver for Clover is continued cohort maturation under our full risk model. Maturing our membership under Clover Assistant-powered care is central to how our model is designed to work. New members create expected near-term pressure because they are earlier in their Clover life cycle. As those members remain with us, engage with Clover Assistant, and become more integrated into our care model, their economics improve over time. We are seeing that dynamic play out today. Our 2025 members created the expected first-year margin headwind last year. This year, that same cohort is in year two, and we are seeing meaningfully stronger economics than we did a year ago. At the same time, our members that joined in 2026 are following a similar early life pattern, as expected. That is the maturation curve we expect, and it is now visible in our results. That is what gives us increasing confidence in 2027. Next year, our 2025 cohort will move into year three, where our historical data shows another meaningful step-up in economics, while our 2026 cohort will move into year two. In other words, we expect to enter 2027 with a substantially larger membership base moving into more economically mature years under our care model. That is the core of our 2027 outlook. As Andrew discussed, our 2027 strategy was not built around a higher star rating. The move to a four and a half star payment year does not change the underlying earnings trajectory we expected from cohort maturation. It simply provided additional flexibility as we finalized our 2027 bids and made decisions across member value, growth, and margin. The ultimate financial benefit will depend on the final economics reflected in our bids and our final 2027 enrollment. We are not providing additional detail on those assumptions today. The important point is that our foundation for 2027 is a larger and more mature membership base, improving cohort economics and a differentiated full risk model where better care can translate into better financial performance. While we are not providing formal guidance for 2027 today, we have increasing confidence in the direction of the business. Our focus now is on executing through the second half of 2026, delivering our first full year of GAAP net income profitability and entering 2027 from a position of strength. With that, I'll turn it back to Andrew. Thanks, Clay. Before we open the call for questions, I'll leave you with one final thought. We've spent the past several years using AI to empower physicians to make better decisions. It's where technology can create the greatest impact in our mission to improve every life, and it's the foundation of everything we've built at Clover. We don't intend to stop there. We're now moving quickly to bring AI into our back office insurance operations themselves. We believe that will help us better support our members, improve speed and accuracy of claims processing, and completely change the way we scale the business with regard to admin expense. This should compound the margin opportunity we expect over time. By doing this, we think AI will drive both aspects of our business. Clinically, it's used to accelerate access to personalized care. On operations, it's used to streamline administrative functions to lower overhead. Taken together, we think the business is very well-positioned for the years ahead. With that, operator, we'd be happy to open it up for questions. Thank you. At this time, if you would like to ask a question, please click on the Raise Hand button, which can be found on the black bar at the bottom of your screen. When it is your turn, you will receive a message on your screen from the host allowing you to talk, and then you will hear your name called. Please accept, unmute your audio and ask your question. We will wait one moment to allow the queue to form. Your first question will come from Richard Close with Canaccord Genuity. Please unmute your audio and ask your question. Yeah. Thanks for the question. Congratulations. In one of the slides, you point to two-thirds of the members are managed with CA. I'm just curious, since you guys have focused in on New Jersey and Georgia the last two cohorts in terms of the growth. What are the percentage of those two cohorts that are managed under CA? Yeah. Hey, Richard. Thanks for the question. Just want to clarify, you're specifically asking about New Jersey and Georgia and the Clover Assistant coverage within those two markets? Yeah. No, just really on, I guess the last two cohorts- Oh, right the percentage of those. Obviously, those two states have been where the focus is, but the two cohorts specifically. Right. Okay. Got you. Members joining in 2025 and 2026. Yes. We're really pleased with the coverage that we've seen there. It's a little bit lower than the two-thirds across our overall population, but you're looking in the low 60s, and then that generally trends up over time. As members kind of stay with Clover for longer periods of time, we generally see that Clover Assistant engagement tick up and meet the higher range of that two-thirds number. Okay. That's helpful. With respect to your comments on the cohorts and maturation from year two to year three, just the 49%, I guess rough math, that's like 77,000 members. How is that split up between year one and year two, just to get some sort of sense in terms of the year two rolling into year three for 2027? Sure thing, Richard. When you think about that, about 21% or so of the membership we see in this year, the new member cohort from 2025 represents about 21%, the 2026 cohort is at about 28. As you're trying to model from 2026 into 2027, those are the figures that I would anchor you on. Obviously, a higher percentage of members will be shifting from year one to year two than year two to year three. Okay, that's helpful. Yeah. just a final question. I appreciate the investments, talking about the investments, with respect to SG&A, I guess it declined sequentially from first quarter to second quarter. Was there anything specific in the second quarter that we should think about? Not particularly. Richard, in the first quarter, I did mention there were a few one-time events that were non-recurring. For instance, the claims adjustment expense that we incurred in the first quarter when our IBNR reserves went up. Really from Q1 to Q2, you had the elimination of those one-time non-recurring events that occurred in the first quarter. Okay. Thank you. Yeah. Thanks. As a reminder, if you would like to enter the queue or re-enter the queue, you may click on the raise hand button at the bottom of the screen. Your next question will come from Jonathan Yong with UBS. Please unmute your audio and ask your question. Hey, guys. Thanks for taking a question. I guess starting with your bids for 2027, can you talk a little bit about how you approached it, did you approach it from a more balanced perspective, or were you moving a little bit more towards your same perspective on there? If you could provide any color on how you were thinking about the cost trend. Were you assuming something similar to what you experienced this year or something improved, just if you could provide any color there? Yeah, sure thing, Jonathan. I'll actually hit the cost trend point first and circle back to the strategy. Underlying cost trends, I would say we're generally not going to assume anything meaningfully different than the large national peers would on the underlying cost trend itself. What is unique about us when you think about 2027 is the cohort maturation that will impact 2027. With a company like Clover that's growing at the rate that we are growing, you're dealing with a little bit more complex movement from 2026 into 2027. We're generally looking at it, yes, through the lens of trend and through the lens of benchmark increase and direct subsidy increase, but we're also looking at it through the lens of how much value is created in 2027 as a result of that cohort maturation. The answer to that question really can inform the growth posture, because ultimately, as you're trying to assess cohort maturation from year two to year three and year one to year two, that really becomes an offset to any near term margin headwind that you may face with bringing on additional year one members. To pull it back around to the root of your question, how did we think about our bids? We really approached our bids in a similar fashion that we have in the past two years. We wanted to put a strong product in the market that we knew we could grow, and we knew we could grow profitably. The impact of our cohort maturation to 2027, I think, positioned us well to do that. Okay. Just given some of the commentary from the nationals about continuing to exit certain markets, et cetera, curious if that was factored within the context of your bids, because obviously I assume that that helped you quite a bit this year. Was just curious if that was factored into your thinking there. Yeah, we definitely did assume continued disruption. When you look at 2025 and 2026, there's been significant disruption in New Jersey and in Georgia. As we were assessing 2027, we definitely had a close eye on what the nationals were saying leading up to their bids, but also some of the local competitors, so that we could get a sense for what they may do heading into 2027. Our expectation certainly is that there would be more disruption, Jonathan, and we did factor that into the bids. Okay, great. Just last one here is, you obviously had a good outcome related to Stars via the court case. I know you guys don't necessarily try to target for Stars, but relative to your internal metrics, how are you performing on the Stars metrics, and do you feel that you'll be able to continue to maintain, whether it be four and a half or four Stars, moving forward as we progress to the next Stars update? Yeah, Jonathan, obviously we're pleased with the Stars outcome, as we said during the commentary. We're always investing in Stars. We're always focusing on making sure we do as well as possible. Plan previews are just about to come out now, we'll have more to talk about here. Traditionally, for the last two years, we've been the number one PPO in the country on HEDIS Star ratings. We've been very pleased with that. We think our technology approach really helps with that. For the other ratings, we're always investing there as well. More to come on that as plan previews come out. Great. Thanks. If you would like to ask a question and enter the queue, you may click on the raise hand button, which can be found at the bottom of your screen. Our next question will come from Dean Rosales with Leerink. Please unmute your audio and ask your question. Hey, guys, thanks for the question. Dean Rosales on for Whit Mayo. With Plan Preview One coming out, just curious really quick your thoughts on how CAHPS are looking, those kind of preliminary data points. Anything you could share on that would be incredibly helpful. Thank you. Hey, Dean. Thanks for the question. Plan Preview One is really just kicking off, so we're not going to comment specifically on any particular domain at this time. As we move closer to October and the release of measurement year 2025 results, we'll speak to that then. No problem. If I could just get a quick one. I guess obviously with this favorable ruling and then subsequent appeal, are you guys assuming this 4.5-star benefit in bids or what's kind of baked into the 2026, 2027 raise or framing? Any sort of nuggets there would be great. Yeah, of course, Dean. CMS has appealed, as we said in the commentary, and that's moving forward. We feel good about the case. We think that the district court had good rationales, had good judgment. We think the judge was very thoughtful, we're feeling good about defending that as it goes into appeal. Just as a reminder for everyone, though, we are paid on 4.5 stars going into next year. We recalculated and we bid against that, we're going into a 4.5-star payment year going into next year. We feel like everything we've got is aligned to executing against that. Great. Thanks so much. To join the queue, you may click on the raised hand button, which can be found on the black bar at the bottom of the screen. We will pause for one moment to assemble the queue. There are no further hands raised at this time. I will now turn the call back over to Andrew Toy. All right. Thanks to everybody for joining us today, and thanks for the thoughtful questions from everyone. We appreciate your continued interest in Clover and the opportunity to share our progress with you, and we look forward to speaking with you all again next quarter. Have a great evening. Thanks.